| abstract |
Administration of sPLA2 inhibitors in combination with statins has been seen to reduce major adverse cardiac events (MACE), inflammatory biomarker levels, and LDL-C levels in subjects who have recently experienced an index of ACS events up to a significantly higher degree than statins alone; these results were not expected given the previous results that demonstrated that statins alone were insufficient to satisfactorily reduce MACE and inflammation in the high-risk population; therefore, methods for the treatment of MACE, the treatment of ACS, are hereby provided to inhibit inflammation and lower cholesterol levels in a subject who has previously experienced an ACS event, with the administration of one or more sPLA2 inhibitors alone or in combination with one or more statins. |